We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+7.77%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$800M
AUM Growth
+$24M
Cap. Flow
+$23.2M
Cap. Flow %
2.9%
Top 10 Hldgs %
39.52%
Holding
76
New
14
Increased
22
Reduced
26
Closed
9

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$25.8M
2
ABT icon
Abbott
ABT
+$21.2M
3
LLY icon
Eli Lilly
LLY
+$14M
4
CELG
Celgene Corp
CELG
+$11.6M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.89M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19M
2
MRK icon
Merck
MRK
+$12.6M
3
MOH icon
Molina Healthcare
MOH
+$12.1M
4
TSRO
TESARO, Inc.
TSRO
+$11.1M
5
ABMD
Abiomed Inc
ABMD
+$8.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$41M 5.13%
2,850,769
+437,899
+18% +$6.02M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$38M 4.75%
+1,752,655
New +$25.8M
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.38B
$34.1M 4.26%
1,131,722
+309,330
+38% +$9.89M
NVS icon
4
Novartis
NVS
$293B
$31.5M 3.94%
419,054
-9,262
-2% -$699K
PFE icon
5
Pfizer
PFE
$143B
$31.5M 3.94%
917,058
-92,329
-9% -$3.15M
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$30.2M 3.78%
712,356
+107,399
+18% +$4.03M
JNJ icon
7
Johnson & Johnson
JNJ
$609B
$29.9M 3.74%
214,349
-21,000
-9% -$2.93M
LJPC
8
DELISTED
La Jolla Pharmaceutical Company
LJPC
$27.5M 3.44%
854,301
+252,801
+42% +$8.26M
COLL icon
9
Collegium Pharmaceutical
COLL
$1.17B
$26.3M 3.29%
1,426,862
-322,595
-18% -$4.62M
PTLA
10
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$26.1M 3.26%
536,414
+30,000
+6% +$1.52M
CELG
11
DELISTED
Celgene Corp
CELG
$24.2M 3.02%
231,830
+102,898
+80% +$11.6M
TDOC icon
12
Teladoc Health
TDOC
$1.7B
$23.8M 2.97%
681,628
-51,751
-7% -$1.72M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.5B
$23.1M 2.88%
258,503
+20,090
+8% +$1.75M
AERI
14
DELISTED
Aerie Pharmaceuticals
AERI
$22M 2.75%
368,797
-4,599
-1% -$279K
ABT icon
15
Abbott
ABT
$175B
$21.9M 2.73%
+382,909
New +$21.2M
KTWO
16
DELISTED
K2M Group Holdings, Inc
KTWO
$21M 2.62%
1,164,412
+267,698
+30% +$5.08M
UNH icon
17
UnitedHealth
UNH
$387B
$18.3M 2.28%
82,904
-15,301
-16% -$3.24M
EW icon
18
Edwards Lifesciences
EW
$49.4B
$17.8M 2.23%
474,300
+76,560
+19% +$2.81M
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
$17.4M 2.17%
441,768
-91,940
-17% -$3.43M
ABMD
20
DELISTED
Abiomed Inc
ABMD
$15.9M 1.99%
84,774
-43,897
-34% -$8.2M
REGN icon
21
Regeneron Pharmaceuticals
REGN
$70.9B
$14.8M 1.85%
39,316
+6,399
+19% +$2.59M
MDT icon
22
Medtronic
MDT
$106B
$14.7M 1.83%
181,610
-99,550
-35% -$7.97M
LLY icon
23
Eli Lilly
LLY
$1.05T
$13.9M 1.73%
+164,200
New +$14M
CI icon
24
Cigna
CI
$74.5B
$13.7M 1.72%
67,615
+22,000
+48% +$4.38M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.82B
$13.3M 1.66%
238,999
+169,900
+246% +$9M
1
2 3 4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
FWA
Fulcrum Wealth Advisors Bellevue, Washington $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM

Sectoral Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sectoral Asset Management held 76 positions worth $800M, up 3.1% from $776M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Sectoral Asset Management's Q4 2017 filing shows 14 new, 22 increased, 26 reduced and 9 closed positions. Its largest new stake was Apellis Pharmaceuticals: 1,752,655 shares worth $38M. The largest sale was Gilead Sciences, an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

  • Sectoral Asset Management's largest Q4 2017 buy was Apellis Pharmaceuticals: 1,752,655 shares worth $38M.
  • Sectoral Asset Management added most to Celgene Corp in Q4 2017, an estimated $11.6M increase.
  • Sectoral Asset Management's biggest Q4 2017 reduction was Merck, cutting an estimated $12.6M.
  • Sectoral Asset Management fully exited Gilead Sciences in Q4 2017, selling an estimated $19M.
  • Sectoral Asset Management's ten largest holdings make up 40% of its $800M portfolio in Q4 2017.
  • Sectoral Asset Management opened 14 new positions and closed 9 in Q4 2017.
  • Sectoral Asset Management's portfolio value rose 3.1% quarter-over-quarter to $800M.

Based on Sectoral Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.